Oman pharmaceuticals continue gaining momentum as the country strengthens its healthcare manufacturing sector. Officials aim to attract more investment while expanding domestic production capabilities. Furthermore, the industry supports economic diversification and long-term industrial growth.
The pharmaceutical market in Oman is expected to reach $1.24 billion by 2031. Industry forecasts estimate steady growth over the coming years. The market was valued at approximately $752.4 million in 2024. Analysts expect an average annual growth rate of 7.4 percent throughout the forecast period.
Government authorities continue promoting investment in pharmaceutical manufacturing and medical technology. They encourage companies to establish production facilities across the country’s economic zones. As a result, Oman continues attracting local and international healthcare investors.
Officials have identified several promising investment opportunities. These include generic medicine manufacturing, vaccine production, biopharmaceutical development, research laboratories, and active pharmaceutical ingredient production.
Medical equipment manufacturing also offers significant growth potential. Companies continue expanding production of surgical instruments and smart healthcare devices. Digital health technologies also remain an important focus for future development.
The government supports these investments as part of its economic diversification strategy. Leaders aim to reduce reliance on imported medicines and healthcare products. Therefore, they continue encouraging local manufacturing across multiple healthcare industries.
Demand for pharmaceutical products continues rising across Oman. Import figures increased from $565 million in 2021 to more than $670 million in 2023. This trend reflects growing healthcare needs and expanding regional demand.
Several major pharmaceutical facilities already operate across the country. These projects are located in special economic zones, industrial cities, and free zones. Together, they strengthen Oman’s manufacturing capacity.
Salalah Free Zone has attracted pharmaceutical investments exceeding $600 million. Several major manufacturers have established production facilities there. These projects continue supporting employment and industrial expansion.
Khazaen Economic City also hosts major pharmaceutical investments. The area includes integrated pharmaceutical manufacturing facilities and biotechnology companies. Veterinary vaccine production also continues expanding within the development.
Madayn industrial cities have attracted more than $100 million in pharmaceutical investments. Specialized manufacturers continue increasing production capacity across multiple healthcare segments. These facilities produce medicines for domestic and international markets.
Sohar Freezone also continues expanding its pharmaceutical manufacturing base. Companies there focus on medicine production and industrial development. New projects continue strengthening supply chains throughout the sector.
Oman also benefits from several natural resources that support pharmaceutical manufacturing. These resources include gypsum, limestone, dolomite, and fish-derived materials. Water treatment infrastructure further strengthens industrial operations.
Medical device manufacturing presents another promising opportunity. Investors continue exploring the production of medical polymers, rubber products, textiles, and healthcare adhesives. These industries complement pharmaceutical manufacturing activities.
Several Omani pharmaceutical companies now export products internationally. Some manufacturers supply medicines to more than 50 countries worldwide. This growing export network strengthens Oman’s position within global healthcare markets.
Large-scale manufacturing projects continue increasing production capacity. Some facilities now produce up to one billion tablets and capsules annually. These investments help meet domestic demand while supporting exports.
Government incentives remain a key attraction for investors. Eligible businesses receive long-term tax exemptions and customs benefits. Investors also benefit from full foreign ownership and flexible capital requirements.
Additional incentives include long-term land agreements and residency options for qualified investors. Some pharmaceutical manufacturers also receive advance purchase agreements. Government procurement policies further encourage domestic production.
Global pharmaceutical demand continues expanding steadily. Healthcare innovation, aging populations, and medical advancements support long-term industry growth. Consequently, Oman aims to strengthen its competitive position within regional healthcare manufacturing.
Overall, Oman pharmaceuticals represent an important part of the country’s future industrial strategy. Continued investment, expanding production, and supportive government policies are expected to drive sustained growth. As new projects become operational, Oman pharmaceuticals will continue strengthening the country’s healthcare sector while creating new economic opportunities and expanding its presence in regional and international markets.
